Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · IEX Real-Time Price · USD
10.01
-0.25 (-2.44%)
At close: May 24, 2024, 4:00 PM
10.03
+0.02 (0.20%)
After-hours: May 24, 2024, 7:59 PM EDT

Iovance Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018 - 2007
Revenue
1.190000
Upgrade
Cost of Revenue
10.760000
Upgrade
Gross Profit
-9.570000
Upgrade
Selling, General & Admin
106.92104.183.6660.2140.85
Upgrade
Research & Development
344.08294.78259.04201.73166.02
Upgrade
Operating Expenses
450.99398.88342.7261.94206.87
Upgrade
Operating Income
-460.56-398.88-342.7-261.94-206.87
Upgrade
Other Expense / Income
-13.04-2.99-0.45-2.36-9.32
Upgrade
Pretax Income
-447.52-395.89-342.25-259.58-197.56
Upgrade
Income Tax
-3.480000
Upgrade
Net Income
-444.04-395.89-342.25-259.58-197.56
Upgrade
Shares Outstanding (Basic)
235159153138124
Upgrade
Shares Outstanding (Diluted)
235159153138124
Upgrade
Shares Change
47.64%3.82%10.92%11.23%27.82%
Upgrade
EPS (Basic)
-1.89-2.49-2.23-1.88-1.59
Upgrade
EPS (Diluted)
-1.89-2.49-2.23-1.88-1.59
Upgrade
Free Cash Flow
-384.11-313.18-265.52-251.93-165.81
Upgrade
Free Cash Flow Per Share
-1.63-1.97-1.73-1.82-1.33
Upgrade
Gross Margin
-804.54%----
Upgrade
Operating Margin
-38734.99%----
Upgrade
Profit Margin
-37345.42%----
Upgrade
Free Cash Flow Margin
-32305.30%----
Upgrade
EBITDA
-414.39-374.76-328.27-250.87-189.43
Upgrade
EBITDA Margin
-34851.89%----
Upgrade
Depreciation & Amortization
33.1321.1413.988.718.12
Upgrade
EBIT
-447.52-395.89-342.25-259.58-197.56
Upgrade
EBIT Margin
-37638.02%----
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).